ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
Study sponsor: Acurx Pharmaceuticals Inc. · ACXP
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-10-03Actual
Enrollment · participants53Actual
Source updated2025-01-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.